Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1/2 MonumenTAL-1 study of talquetamab, an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody. Talquetamab targets both GPRC5D, a novel target on multiple myeloma cells, and CD3 on T cells, activating the body’s immune system to fight this blood cancer.[1] Results from the study suggest patients with relapsed or refractory multiple myeloma who received a median of five prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agen...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Why This Top-Notch IPO Stock Just Broke Out In Bullish Volume
Recent initial public offering Arcellx (ACLX) forged a $325 million multiple myeloma deal with Gilead Sciences (GILD) on Friday, and the IPO stock broke out.X The news comes in lockstep with promising long-term results for Arcellx's multiple myeloma treatment. Every patient with at least one month…#usarcellx #gileadsciences #kitepharma #ipostock #aclx #crs #gilead #myelomadrug #marketsmithcom #arcellx (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2022 Category: Consumer Health News Source Type: news
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for talquetamab for the treatment of patients with relapsed or refractory multiple myeloma. Talquetamab is an investigational, off-the-shelf (ready to use), bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and separately targets CD3 on T cells.[1]“Despite the therapies that have been developed for the treatment of m...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., Dec. 9, 2022 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for t... Biopharmaceuticals, Oncology Janssen Pharmaceutical Companies, Johnson & Johnson, talquetamab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 9, 2022 Category: Pharmaceuticals Source Type: news
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 9, 2022– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for talquetamab for the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 9, 2022 Category: Drugs & Pharmacology Source Type: news
Significant Treatment Attrition Rate Seen in Multiple Myeloma
In patients receiving autologous stem cell transplant, 57.6 percent advanced to second - line treatment, 32.6 percent to third - line (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 22, 2022 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news
Significant Treatment Attrition Rate Seen in Multiple Myeloma
TUESDAY, Nov. 22, 2022 -- There is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue of Leukemia& Lymphoma.
Victor H. Jimenez-Zepeda, M.D., from Alberta... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 22, 2022 Category: Pharmaceuticals Source Type: news
Blenrep for Multiple Myeloma Withdrawn From US Market Blenrep for Multiple Myeloma Withdrawn From US Market
The manufacturer is pulling the drug from the market at the request of the FDA following disappointing results from a large phase 3 confirmatory trial.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 22, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
GSK to withdraw Blenrep ’s U.S. marketing authorization after FDA request
GSK PLC GSK, The pharmaceutical giant said the request comes after its Dreamm-3 Phase 3 study in patients with relapsed or refractory multiple myeloma didn’t meet its primary endpoint of progression-free survival. The company said patients treated with Blenrep therapy who have been already…#gskplc #gsk #plc #multiplemyeloma #sabineluik #program #michaelsusin #blenreptherapy #multiple #myeloma (Source: Reuters: Health)
Source: Reuters: Health - November 22, 2022 Category: Consumer Health News Source Type: news
Teclistamab for MM: Lifesaver or'Cause of Death'? Teclistamab for MM: Lifesaver or'Cause of Death'?
Teclistamab (Tecvayli) has been approved for relapsed/refractory multiple myeloma patients who have received at least four lines of therapy; typically, such patients have just a few weeks to live.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 18, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
For Camp Lejeune Victims Exposed to Toxic Water, a New Law Promises Compensation —and Closure
Many of Ann Johnson’s life milestones were marked at Camp Lejeune, a sprawling U.S. Marine Corps base camp on the North Carolina coast. She moved to the base in 1982, when her stepfather was stationed there. In 1983, she graduated from Camp Lejeune High School. In 1984, she got married and, at the age of 18, gave birth to her first child at the on-base hospital.
Johnson had a difficult pregnancy, gaining 120 pounds due to a complication that leads to excess amniotic fluid. In retrospect, she says, this was the first sign that something was wrong. Then, on the day her daughter, Jacquetta, was born, she didn’t cr...
Source: TIME: Health - November 16, 2022 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Source Type: news
Options Explored for MM That Relapses After BCMA CAR T Therapy
WEDNESDAY, Nov. 9, 2022 -- Patients with multiple myeloma that relapses after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR T) therapy can potentially be treated with multiple lines of salvage therapy, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 9, 2022 Category: Pharmaceuticals Source Type: news
Myeloma Patients Who Relapse After CAR T-Cell Therapy Have Options
(MedPage Today) -- Patients with multiple myeloma who relapse after treatment with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can be salvaged with multiple lines of therapy, a retrospective study suggested... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 4, 2022 Category: Hematology Source Type: news
Pfizer's elranatamab granted FDA Breakthrough Therapy Designation for relapsed or refractory multiple myeloma
Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of people with relapsed or refractory multiple myeloma (RRMM). Elranatamab is a B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb). (Source: World Pharma News)
Source: World Pharma News - November 4, 2022 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
